1. Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis
- Author
-
Sa Ye, Ying Chen, Hongbin Zhou, Jiuke Li, and Zhewen Chen
- Subjects
Male ,Nitric oxide (NO) ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Nitric Oxide ,Fraction of exhaled nitric oxide (FeNO) ,Gastroenterology ,Nitric oxide ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Surgical oncology ,Internal medicine ,Genetics ,medicine ,Humans ,Lung cancer ,Pathological ,RC254-282 ,business.industry ,Research ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Control subjects ,respiratory tract diseases ,030228 respiratory system ,Oncology ,chemistry ,Therapy Effect ,030220 oncology & carcinogenesis ,Meta-analysis ,Exhaled nitric oxide ,Disease Progression ,Female ,business - Abstract
Background Nitric oxide (NO) plays an important role in lung cancer. However, the results of previous studies about NO in the occurrence, progress and therapy were not consistent. Therefore, we conducted a meta-analysis to evaluate the relationship between NO and lung cancer. Method We carried out comprehensive search in the databases, and collected related studies. The data of fraction of exhaled nitric oxide (FeNO) or blood NO in different populations (lung cancer patients and control subjects) and different time points (before therapy and after therapy) were extracted by two investigators. A random effect model was applied to analyze the differences of FeNO and blood NO in different populations and different time points. To further compare NO level of each subgroup with different pathological types and different stages, a network meta-analysis (NMA) was performed. Results Fifty studies including 2551 cases and 1691 controls were adopted in this meta-analysis. The FeNO (SMD 3.01, 95% CI 1.89–4.13, p p p > 0.05) and blood NO level (SMD -0.36, 95% CI -1.08-0.36, p > 0.05) was observed between pretreatment and posttreatment in all patients. However, FeNO level elevated (SMD 0.28, 95% CI 0.04–0.51, p = 0.02) and blood NO level decreased in NSCLC patients (SMD -0.95, 95% CI -1.89-0.00, p = 0.05) after therapy. Conclusion FeNO and blood NO level would contribute to diagnosis of lung cancer and evaluation of therapy effect, especially for NSCLC patients.
- Published
- 2021